Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00531206 |
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Aptivus (tipranavir) in combination with low-dose Norvir (ritonavir) will durably suppress viral load and may achieve suppression of viral load below the limit of detection.
Condition |
---|
HIV Infections |
Study Type: | Observational |
Official Title: | Observational Non-Interventional Study About Antiretroviral Combination Treatment With Aptivus in Combination With Low-Dose Ritonavir in HIV Type 1 Infected Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Boehringer Ingelheim | |
Berlin, Germany | |
Boehringer Ingelheim | |
Düsseldorf, Germany | |
Boehringer Ingelheim | |
München, Germany | |
Boehringer Ingelheim | |
Frankfurt/Main, Germany | |
Boehringer Ingelheim | |
Stuttgart, Germany | |
Boehringer Ingelheim | |
Karlsruhe, Germany | |
Boehringer Ingelheim | |
Aachen, Germany | |
Boehringer Ingelheim | |
Hamburg, Germany | |
Boehringer Ingelheim | |
Saarbrücken, Germany | |
Boehringer Ingelheim | |
Oldenburg, Germany | |
Boehringer Ingelheim | |
Leipzig, Germany | |
Boehringer Ingelheim | |
Mainz, Germany | |
Boehringer Ingelheim | |
Hannover, Germany | |
Boehringer Ingelheim | |
Gießen, Germany | |
Boehringer Ingelheim | |
Köln, Germany | |
Boehringer Ingelheim | |
Münster, Germany | |
Boehringer Ingelheim | |
Osnabrück, Germany | |
Boehringer Ingelheim | |
Wuppertal, Germany | |
Boehringer Ingelheim | |
Bremen, Germany | |
Boehringer Ingelheim | |
Nürnberg, Germany | |
Boehringer Ingelheim | |
Magdeburg, Germany | |
Boehringer Ingelheim | |
Krefeld, Germany | |
Boehringer Ingelheim | |
Dortmund, Germany | |
Boehringer Ingelheim | |
Homburg/Saar, Germany | |
Boehringer Ingelheim | |
Halle/Saale, Germany | |
Boehringer Ingelheim | |
Freiburg, Germany | |
Boehringer Ingelheim | |
Erlangen, Germany |
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 1182.112 |
Study First Received: | September 17, 2007 |
Last Updated: | December 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00531206 |
Health Authority: | Germany: |
Virus Diseases Sexually Transmitted Diseases, Viral Ritonavir HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes Tipranavir |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |